-
Mashup Score: 2Our Vision: The Elimination of Cancer - 2 year(s) ago
Our innovative solutions have paved the way in oncology for more than 30 years, and we are determined to meet this public health crisis and transform cancer from a deadly disease to one that is preventable and curable.
Source: Content Lab U.S.Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 15Dr. Lynn M. Schuchter Elected ASCO President for 2023-2024 Term - 2 year(s) ago
Seven new members were also elected to the ASCO Board of Directors and Nominating Committee.
Source: ASCO ConnectionCategories: Latest Headlines, Oncologists1Tweet-
RT @ASCO: šCongratulations to Dr. @lynn_schuchter on being elected to serve as ASCO President! šhttps://t.co/l73CeN9zsU https://t.co/SJcOANā¦
-
-
Mashup Score: 2Penn Medicine Updates in Oncology 2021 - Panel Discussion - 3 year(s) ago
This is “Panel Discussion” by AJI Events on Vimeo, the home for high quality videos and the people who love them.
Source: VimeoCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @PennMDForum: ICYMI - Donāt miss the recent virtual annual Updates in Oncology meeting, now available online at https://t.co/eOQhjD7QFr.ā¦
-
-
Mashup Score: 5
Background Some patients with human papillomavirus (HPV)āassociated oropharyngeal squamous cell carcinoma (OPSCC) do not receive guidelineārecommended postoperative radiation therapy (PORT) followin…
Source: Wiley Online LibraryCategories: Hem/Oncs, Latest HeadlinesTweet-
Great collaborative effort @PennCancer @Penn_ENT evaluating outcomes for patients with HPV+ HNSCC that do not receive recommended adjuvant therapy after TORS. #HNCSM https://t.co/AL58hjDq1U https://t.co/Hkez8ieuDn
-
-
Mashup Score: 1Re-entry - 3 year(s) ago
After the Blitz
Source: onservice.substack.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @MarkRobsonMD: Re-entry by @MarkRobsonMD https://t.co/4RIPzw37Wp New post. Thanks for reading
-
-
Mashup Score: 3Doximity - 3 year(s) ago
Over a million U.S. healthcare professionals as verified members. Largest network of MDs and other healthcare professionals. New to Doximity? Find your profile and join for free.
Source: auth.doximity.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @PennMDForum: The @USnews Best Hospitals survey polls are now open: https://t.co/3i6YzXrVtD We're so proud of our clinical teams. Donā¦
-
-
Mashup Score: 0CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors - Full Text View - ClinicalTrials.gov - 3 year(s) ago
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet-
Excited to participate in the trial first evaluating this agent. https://t.co/tICB64uiXm
-
-
Mashup Score: 2WCLC 2020: Updates from the CHRYSALIS trial and what it means for patients with NSCLC - ecancer - 3 year(s) ago
In this expert discussion Dr Joshua Bauml and Dr Joshua Sabari speak about the updates from the CHRYSALIS trial and what it means for patients with NSCLC.
Source: ecancer.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
I enjoyed speaking with @JSabari about updated data on amivantamab that he presented at #WCLC20 through an @ecancer Expert Discussion. Please see the link below for his valuable insights! https://t.co/67WXZEGZdY
-
-
Mashup Score: 4New Horizons in EGFR-Mutated NSCLC: Broadening the Impact of Precision Testing in the Context of an Expanding Treatment Landscape - 3 year(s) ago
I participated in āNew Horizons in EGFR-Mutated NSCLC: Broadening the Impact of Precision Testing,ā a CME/MOC/CC activity from @PeerView
Source: learn2.peerview.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @SpeakJen: See a new #NSCLC activity via @PeerView @MEArcila @ZpiotrowskaMD @jbauml #EGFR mutant #lungcancer #CME https://t.co/s7akwrrX75
-
-
Mashup Score: 2
Oncology Newsburst
Categories: Hem/Oncs, Latest HeadlinesTweet-
Notably this type of mutation were included in the expanded approval granted to afatinib by the @FDAOncology https://t.co/TqHWprEnTl #LCSM #WCLC20
-
Today is #WorldCancerDay. So honored to work at a company that is committed to #CloseTheCareGap by bringing novel therapies to patients who need them around the world. #MyCompany https://t.co/12GMn0hLa1 https://t.co/xwEeTCZGKt